Marksans Pharma acquires QliniQ B.V.

Marksans Pharma has acquired 100% of the share capital of QliniQ B.V., a Netherlands-based pharmaceutical company, for euro 7.5 million. This strategic acquisition aims to expand Marksans Pharma's presence in regulated European markets, particularly the Netherlands, by gaining direct access to sales, marketing, and distribution capabilities. QliniQ B.V. operates a portfolio of niche pharmaceuticals and medical devices across women's health, dermatology, and respiratory care, with established relationships with wholesalers, pharmacies, hospitals, and insurers in the Netherlands. The deal is expected to bolster Marksans Pharma's forward-integration strategy and enhance its ability to commercialize existing and future products across Europe. Mark Saldanha, Chairman and Managing Director of Marksans Pharma, and Albert de Bruijn and Raymond Lansink, Board Members and Shareholders of QliniQ B.V., all expressed positive outlooks on the acquisition's potential for growth and value creation.